Nutrition & Care
Q1 2022
The Nutrition & Care segment increased sales considerably compared with the prior-year quarter. Both divisions contributed to the increase with significant sales growth.
|
Nutrition & Care |
Care Chemicals |
Nutrition & Health |
|---|---|---|---|
Volumes |
7.9% |
4.5% |
15.6% |
Prices |
20.7% |
24.9% |
11.2% |
Portfolio |
–2.5% |
–2.5% |
–2.6% |
Currencies |
2.5% |
1.8% |
3.9% |
Sales |
28.6% |
28.7% |
28.3% |
Sales growth was driven by significantly higher prices in all business areas in both divisions, which were able to pass on increased prices for energy and raw materials.
Sales performance was supported by significantly higher volumes. Volume growth in the Nutrition & Health division was driven by the animal nutrition and pharmaceutical businesses. In the Care Chemicals division, sales volumes rose in the personal care solutions business and in the oleo surfactants and alcohols business.
Positive currency effects, mainly relating to the U.S. dollar and the Chinese renminbi, had a slightly positive impact on sales.
Portfolio effects from the sale of the production site in Kankakee, Illinois, reduced sales in both divisions.
The segment’s income from operations (EBIT) before special items was considerably above the first quarter of 2021. Higher EBIT before special items in the Care Chemicals division was primarily driven by positive volume development. Earnings growth in the Nutrition & Health division was attributable to higher margins. This more than compensated for higher fixed costs, mainly from higher depreciation following the startup of the vitamin A plant expansion in Ludwigshafen, Germany, in the second quarter of 2021.
|
|
2022 |
2021 |
+/– |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales to third parties |
|
1,971 |
1,533 |
28.6% |
||||||||||
of which Care Chemicals |
|
1,363 |
1,059 |
28.7% |
||||||||||
Nutrition & Health |
|
608 |
474 |
28.3% |
||||||||||
Income from operations before depreciation, amortization and special items |
|
351 |
316 |
11.0% |
||||||||||
Income from operations before depreciation and amortization (EBITDA) |
|
354 |
313 |
13.0% |
||||||||||
Depreciation and amortizationa |
|
107 |
98 |
9.4% |
||||||||||
Income from operations (EBIT) |
|
246 |
215 |
14.6% |
||||||||||
Special items |
|
3 |
–3 |
. |
||||||||||
EBIT before special items |
|
244 |
218 |
11.8% |
||||||||||
Assets (March 31) |
|
7,738 |
6,579 |
17.6% |
||||||||||
Investments including acquisitionsb |
|
107 |
100 |
6.8% |
||||||||||
Research and development expenses |
|
40 |
40 |
0.4% |
||||||||||
|
||||||||||||||